Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single and Multiple Oral BAY1101042 Tablet Doses in Healthy Male Subjects
2019年8月16日 更新者：Bayer
Single/Multiple Dose Escalation Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAY1101042 Given as 5 mg MR Tablet After Single Oral Dosing Followed by Once Daily Dosing for 7 Days in 12 Healthy Male Subjects Per Dose Step in a Randomized, Placebo Controlled, Single Blind, Group Comparison Design
To investigate the safety, tolerability, pharmacokinetics and effects of BAY1101042 in healthy male subjects after a single oral dose and multiple once daily dosing for 7 days
研究概览
研究类型
介入性
注册 (实际的)
96
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习地点
-
-
Nordrhein-Westfalen
-
Mönchengladbach、Nordrhein-Westfalen、德国、41061
- CRS Clinical-Research-Services Mönchengladbach GmbH
-
Wuppertal、Nordrhein-Westfalen、德国、42113
- CRS Clinical Research Services Wuppertal GmbH
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 45年 (成人)
接受健康志愿者
是的
有资格学习的性别
男性
描述
Inclusion Criteria:
- The informed consent must be signed before any study specific tests or procedures are done.
- Healthy male subject.
- Age: 18 to 45 years (inclusive) at the screening.
- Body mass index (BMI): above/equal 18 and below/equal 29.9 kg/m2.
- Ability to understand and follow study-related instructions.
Exclusion Criteria:
- Pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal.
- Subjects with thyroid disorders as evidenced by assessment of thyroid stimulating hormone (TSH) levels outside the normal reference range at screening.
- Regular use of medicines.
- Smoking more than 10 cigarettes daily.
- Systolic blood pressure below 100 or above 145 mmHg (at screening).
- Diastolic blood pressure below 50 or above 90 mmHg (at screening).
- Heart rate below 50 or above 90 beats/ min (at screening).
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：其他
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Single/multiple doses of 10 mg BAY1101042 or placebo
Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
|
Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
|
|
实验性的：Single/ multiple doses of 20 mg BAY1101042 or placebo
Single oral dose of 20 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
|
Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
|
|
实验性的：Single/ multiple doses of 30 mg BAY1101042 or placebo
Single oral dose of 30 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
|
Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
|
|
实验性的：Single/ multiple doses of 40 mg BAY1101042 or placebo
Single oral dose of 40 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
|
Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
|
|
实验性的：Single/ multiple doses of 50 mg BAY1101042 or placebo
Single oral dose of 50 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
|
Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
|
|
实验性的：Optional: Single/multiple doses of 5 mg BAY 1101042 or placebo
Single oral dose of 5 mg BAY1101042 MR tablets or corresponding placebo followed by once daily dosing for 7 days
|
Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of treatment emergent adverse events (TEAEs)
大体时间：Approximately 19 days
|
Assessment of treatment emergent adverse events from first study drug intake until follow up
|
Approximately 19 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
AUC(0-24) of BAY1101042
大体时间：At day 1
|
AUC(0-24): area under the concentration vs. time curve from zero to 24 hours after single dose
|
At day 1
|
|
AUC(0-24)/D of BAY1101042
大体时间：At day 1
|
AUC(0-24)/D: dose-normalized area under the concentration vs. time curve from zero to 24 hours after single dose
|
At day 1
|
|
Cmax of BAY1101042
大体时间：At day 1
|
Cmax: maximum observed drug concentration after single dose
|
At day 1
|
|
Cmax/D of BAY1101042
大体时间：At day 1
|
Cmax/D: dose-normalized maximum observed drug concentration after single dose
|
At day 1
|
|
AUCτ,md of BAY1101042
大体时间：At day 9
|
AUCτ,md: area under the concentration vs. time curve for the actual dosing interval after multiple dose
|
At day 9
|
|
AUCτ,md/D of BAY1101042
大体时间：At day 9
|
AUCτ,md/D: dose-normalized area under the concentration vs. time curve for the actual dosing interval after multiple dose
|
At day 9
|
|
Cmax,md of BAY1101042
大体时间：At day 9
|
Cmax,md: maximum observed drug concentration after multiple dose
|
At day 9
|
|
Cmax,md/D of BAY1101042
大体时间：At day 9
|
Cmax,md/D: dose-normalized maximum observed drug concentration after multiple dose
|
At day 9
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2017年8月16日
初级完成 (实际的)
2019年4月30日
研究完成 (实际的)
2019年7月24日
研究注册日期
首次提交
2017年8月4日
首先提交符合 QC 标准的
2017年8月15日
首次发布 (实际的)
2017年8月16日
研究记录更新
最后更新发布 (实际的)
2019年8月19日
上次提交的符合 QC 标准的更新
2019年8月16日
最后验证
2019年8月1日
更多信息
与本研究相关的术语
关键字
其他研究编号
- 18747
- 2017-001212-11 (EudraCT编号)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.
BAY1101042的临床试验
-
Bayer完全的糖尿病性视网膜病变捷克语, 瑞士, 西班牙, 丹麦, 美国, 保加利亚, 葡萄牙, 荷兰, 英国, 斯洛伐克, 德国, 波兰, 拉脱维亚, 罗马尼亚